EAST BRUNSWICK, N.J., Jan. 28 (HSMN NewsFeed) — Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced that its biologics license application (BLA) for pegloticase for treatment-failure gout will be reviewed by the Arthritis Advisory Committee ap…
Biopharmaceuticals, FDA
Savient Pharmaceuticals, pegloticase, urate oxidase, gout

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Savient Announces FDA’s Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients”
Leave a Comment